Schiffmann I, Scheiderbauer J,Riemann-Lorenz K, Heesen C.In their paper, De Stefano et al. Describe the reduction of the percentage brain volume change (PBVC) in patients with relapsing remitting multiple sclerosis (RRMS treated with the purine analog cladribine over a period of 24 months. While we highly appreciate the aim of looking at atrophy rates in new MS treatments, we would like to point out that the calculations and figures used may be misleading.
Mult Scler. 2018 Sep;24(10):1387-1388
Link to Pubmed